



*one 12-17 year old participant wrongly randomised to 6-11 year age group at short interval

**one participant originally randomised to short interval ChAdOx1 arm received a delayed second dose at the long interval dose timepoint due to meeting temporary eligibility criteria


6-11 years D112 interval



12-17 years 112 day interval




12-17 years 28 day interval



Groups		Anti-spike in-house ELISA GMT (95% CI) [EU/ml]			
		V1	V2	V2 + 28 days	D364
6-11 years, 112-day interval	ChAdOx1 nCoV-19	1.5 (1-2), 77	405 (311-528), 69	2310 (1700- 3138), 48	3109 (2127- 4544), 54
	MenB	2 (1-4), 16	2 (1-4), 18	2 (1-2), 9	54 (8-379), 9
12-17 years, 112-day interval	ChAdOx1 nCoV-19	2 (1-2), 53	338 (243-470), 52	1963 (1575- 2448), 45	8265 (5291- 12911), 45
	MenB	1 (1-1), 12	5 (1-17), 11	4.5 (1-17), 11	9321 (1296- 67041), 7
12-17 years, 28-day interval	ChAdOx1 nCoV-19	1.8 (1-2), 47	634 (497-810), 45	1194 (908- 1568), 45	3738 (2172- 6433), 38
	MenB	3 (1-5), 13	2 (1-5), 14	4 (2-10), 13	3293 (779- 13916), 9

		ELISpot in-house SFC per 10 ⁶ PBMCs GM (95% CI)				PseudoNA (IC50, Mean)			
		V1	V2	V2 + 28 days	D364	V1	V2	V2 + 28 days	D364
6-11 years, 112-day interval	ChAdOx1 nCoV-19	26 (22- 31), 73	119 (90- 158), 61	104 (79- 137), 39	229 (171- 305), 50	1 (1- 2), 80	258 (23- 493), 68	2436 (767- 4104), 49	1410 (1033- 1788), 37
	MenB	21 (16- 28), 18	22 (14-35), 13	19 (12-32), 6	66 (30-147), 8	-	-	-	2.5 (0-0), 1
12-17 years 112-day interval	ChAdOx1 nCoV-19	43 (33- 55), 46	239 (187- 306), 45	138 (97- 195), 35	287 (195- 421), 40	1 (1- 4), 50	352 (134- 839), 48	415 (306- 524), 44	783 (-791- 2357), 4
	MenB	43 (24-76), 11	64 (21-192), 11	30 (12-77), 8	226 (11- 464), 6	0 (0-0), 12	10 (-12- 33), 12	1064 (-1009- 3137), 10	-
12-17 years, 28-day interval	ChAdOx1 nCoV-19	33 (26-43), 43	295 (229- 381), 45	256 (188- 348), 42	217 (143- 329), 40	0 (0-0), 49	172 (-7- 352), 46	247 (113- 381), 47	1191 (710- 1673), 17
	MenB	33 (20-54), 14	23 (15- 34), 14	22 (15-32), 14	262 (86- 800), 9	0 (0-0), 15	2 (-2, 6), 15	3250 (-39- 104), 12	2819 (273- 5364), 6


Group	MenB arm (n=51)			ChAdOx1 nCoV-19 arm (n=211)		
	Total episodes	Symptomatic episodes	Asymptomatic episodes	Total episodes	Symptomatic episodes	Asymptomatic episodes
6-11 years, 112-day interval (n=112)	11	11	0	42	33	9
12-17 years, 112-day interval (n=75)	0	0	0	23	19	4
12-17 years, 28-day interval (n=76)	4	3	1	30	20	10
Total	15	14	1	95	72	23




Number at risk

Strata	0	100	200	300	400
chad=0	42	30	18	6	0
chad=1	192	176	106	21	0


Time in days




6-11 years 112 day interval



12-17 years 112 day interval



12-17 years 28 day interval



Groups	Anti-spike in-house ELISA (GMT, EU/ml)			
	V1	V2	V2 + 28 days	D364
6-11years, 112-day interval	1 (1,1), 4	659 (48, 8985), 4	2794 (349, 22389), 4	796 (161, 3948), 4
12-17 years 112-day interval	1 (1,2), 6	856 (108, 6789), 6	2488 (824, 7508), 6	1432 (337, 6083), 6
12-17 years, 28-day interval	3 (0,62), 3	1292 (156, 10703), 3	2506 (423, 14844), 3	392 (24, 6493), 3

Appendix 1

Line listing of SAEs reported

1. Tonsillitis
2. Ovarian mass
3. Appendicitis
4. Testicular torsion
5. Pituitary macroadenoma